Clinical trials: Nonalcoholic Fatty Liver
Type 2 Diabetes, Non-alcoholic Fatty Liver Disease
Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
The effects of empagliflozin treatment on hepatocellular lipid content, liver energy metabolism and body composition will be investigated in a multicentre, prospective, placebo-controlled, double-blind, randomized, 2-arm…
- Trial name
- EmLiFa (NCT02637973)
- Testing
- Empagliflozin
- Where
- 5 sites in Germany
- Volunteers
- 84 people
- Sponsor
- The Deutsche Diabetes Forschungsgesellschaft e.V.
Fatty Liver
Effect of Focused Ultrasound on Abdominal and Intrahepatic Fat in Patients With Non-alcoholic Fatty Liver Disease
In recent years, a number of modalities have become available for the noninvasive reduction of adipose tissue. One of those is high intensity focused ultra sound (HIFU).
- Trial name
- NCT04161703
- Testing
- focused ultrasound, diet and exercise, diet and exercise
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
Study of the NAFLD in CKD Patients Using Fibroscan Study
Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut University Hospitals
The aim of our study is: 1. The early detection of NAFLD in CKD patients with different stages (stage I to IV) to avoid progression to liver fibrosis. 2.
- Trial name
- NCT04482153
- Testing
- fibroscan
- Volunteers
- 80 people
- Sponsor
- Assiut University
Non-alcoholic Fatty Liver Disease
Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease
This study aims to assess the safety and tolerability of AMG 609 when administered subcutaneously as single doses in participants with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT04857606
- Testing
- AMG 609
- Where
- 10 sites in United States
- Volunteers
- 47 people
- Sponsor
- Amgen
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis
This study is a Phase 1, first-in-human single-dose escalation and multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of OA-235i in subjects with nonalcoholic steatohepatitis.
- Trial name
- NCT05680233
- Testing
- OA-235i (4 mg), OA-235i (8 mg), OA-235i (16 mg)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Oasis Pharmaceuticals, LLC
Nonalcoholic Fatty Liver Disease
Evaluation of the Effects of a Low Free Sugar Diet in Patients With Nonalcoholic Fatty Liver Disease
To study the effects of a low free sugar diet on lipid profile, glycemic indices, liver enzymes, inflammatory factors and hepatic steatosis and fibrosis in patients with Nonalcoholic fatty liver disease, 50 patients who referred…
- Trial name
- NCT04369521
- Testing
- low free sugar diet
- Where
- 2 sites in Iran
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
Nonalcoholic Fatty Liver Disease
Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is a rapidly growing epidemic worldwide and is an increasingly important etiology of chronic liver disease and hepatocellular carcinoma.
- Trial name
- NCT04988204
- Testing
- Diabetes Prevention Program
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease
Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery
The purpose of this study is to evaluate imaging and other biomarkers of non-alcoholic fatty liver disease before and after bariatric surgery.
- Trial name
- BARI (NCT03294850)
- Testing
- Bariatric surgery, HepQuant SHUNT Dual Cholate Liver Diagnostic Kit
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Fatty Liver, Obesity
Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)
The objective of this clinical trial, a pilot study, is to assess the impact of nicotinamide (NAM) on individuals with hepatic fibrosis.
- Conditions
- Fatty Liver, Obesity, Hepatic Fibrosis, NAFLD
- Trial name
- NICOFIB (NCT06599918)
- Testing
- Nicotinamide
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Non-Alcoholic Fatty Liver Disease
Macrophage-mediated Inflammation in White Adipose Tissue and Non-alcoholic Fatty Liver Disease.
Non-alcoholic fatty liver disease (NAFLD) is present in one third of the population and due to its potential to cause irreversible liver damage and liver cancer, it is a significant health burden.
- Trial name
- NCT04059068
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Imperial College London
Non-alcoholic Fatty Liver Disease
To Explore the Effectiveness of Jing-Si Herbal Tea Against Non-alcoholic Fatty Liver Disease
The aim of this study is to explore the effectiveness of Jing-Si Herbal Tea on improving the Non-alcoholic fatty liver disease patients
- Trial name
- NCT05858138
- Testing
- Jing-Si Herbal Tea
- Where
- Taiwan
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Taichung Tzu Chi Hospital
Non-Alcoholic Steatohepatitis (NASH)
Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
The primary objective of this study is to evaluate the safety and tolerability of GS-4997 (selonsertib [SEL]) alone or in combination with simtuzumab (SIM) in adults with nonalcoholic steatohepatitis (NASH) and fibrosis stages…
- Trial name
- NCT02466516
- Testing
- SEL, SIM
- Where
- 28 sites in United States, Canada
- Volunteers
- 72 people
- Sponsor
- Gilead Sciences
Obesity, Morbid, Non-Alcoholic Fatty Liver Disease
The Effects of Bariatric Surgeries on Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease. In the absence of chronic alcohol abuse or other liver diseases, NAFLD incorporates a wide spectrum of liver pathologies and is defined…
- Trial name
- NCT01619215
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 35 people
- Sponsor
- King Saud University
Fatty Liver, Nonalcoholic, Meal Time
Hepatic Glycogen and Fat Oxidation
Excessive fat in the liver is associated with impairments in metabolic health. Low levels of DNL and high levels of hepatic fat oxidation are considered to be protective.
- Conditions
- Fatty Liver, Nonalcoholic, Meal Time, Fasting, Glycogen Depletion
- Trial name
- NCT03593343
- Testing
- Overnight fasting duration
- Where
- Netherlands
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Fatty Liver Disease
A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795
The purpose of the study is to assess the safety and tolerability of single and multiple subcutaneous (SC) doses of JNJ-75220795.
- Trial name
- NCT04844450
- Testing
- JNJ-75220795
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Janssen Research & Development, LLC
Non-Alcoholic Fatty Liver Disease
The Clock Thickens: Morning or Evening Training for the Treatment of NAFLD?
The goal of this clinical trial is to investigate the different effect of morning and evening exercise training in individuals with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- TikTac (NCT05987748)
- Testing
- Exercise training
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Leiden University Medical Center
Nonalcoholic Fatty Liver Disease, Hepatic Steatosis
A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection
The purpose of this study is to measure the effect of a short-term low calorie diet on patients with a Body Mass Index (BMI) over 25 who are undergoing liver surgery.
- Conditions
- Nonalcoholic Fatty Liver Disease, Hepatic Steatosis, Steatohepatitis
- Trial name
- NCT01645852
- Testing
- Optifast 800
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Non-Alcoholic Fatty Liver Disease
Prevention of NAFLD in Hispanic Children
This is a 2 year clinical trial testing an intensive intervention to reduce dietary sugars as a means to prevent non-alcoholic fatty liver disease (NAFLD) in pre-pubertal Hispanic children.
- Trial name
- NCT05292352
- Testing
- LFSD
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Emory University
Non-alcoholic Steatohepatitis (NASH)
Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)
Collection of clinical and genetic data to help identify individuals that carry genetic variants of known importance in Non-alcoholic Steatohepatitis (NASH)
- Trial name
- NCT05423327
- Testing
- No Intervention
- Where
- 50 sites in United States, Brazil and 3 more
- Volunteers
- 5,311 people
- Sponsor
- Regeneron Pharmaceuticals
Nonalcoholic Steatohepatitis (NASH)
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of CS0159 in subjects with Non-Alcoholic Steatohepatitis (NASH)
- Trial name
- NCT05591079
- Testing
- CS0159 (Linafexor)
- Where
- 17 sites in United States
- Volunteers
- 99 people
- Sponsor
- Cascade Pharmaceuticals, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.